Narrow search
Showing 1 - 10 of 2,804
Cover Image
Changes in the effectiveness of state Medicaid drug program cost-containment policies following OBRA 1990
Moore, William J.; Pracht, Etienne E. - In: The American journal of economics and sociology 66 (2007) 5, pp. 901-924
Persistent link: https://www.econbiz.de/10003633860
Cover Image
Complement and substitute effects of prescription drug insurance on Medicare covered services
Powell, Melanie Paige - 2003
Persistent link: https://www.econbiz.de/10003385472
Cover Image
Modelling medicare and pharmaceutical benefits scheme (PBS) utilisation and costs
Raymond, Chris; Parsons, Brett - In: Modelling our future : population ageing, health and …, (pp. 197-211). 2007
Persistent link: https://www.econbiz.de/10003551920
Cover Image
The demand for Medicare Part D prescription drug coverage : evidence from four waves of the retirement perspectives survey
Heiss, Florian; McFadden, Daniel; Winter, Joachim - In: Explorations in the economics of aging, (pp. 159-182). 2011
Persistent link: https://www.econbiz.de/10008986961
Cover Image
Medicare Part B intensity and volume offset
Brunt, Christopher S. - In: Health economics 24 (2015) 8, pp. 1009-1026
Persistent link: https://www.econbiz.de/10011318456
Cover Image
Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance
Yang, Bong M.; Bae, Eun-young; Kim, Jinhyun - In: Health affairs : at the intersection of health, health … 27 (2008) 1, pp. 179-187
Persistent link: https://www.econbiz.de/10003663169
Cover Image
Pharmaceutical benefit scheme and cost containment in Taiwan's National Health Insurance
Huang, Weng-Foung; Chiang, Hung-Chi - In: Journal of pharmaceutical finance, economics & policy 12 (2003) 2, pp. 133-149
Persistent link: https://www.econbiz.de/10002185666
Cover Image
Sustainability of pharmaceutical expenditures in the German social health care system
Hammerschmidt, Thomas - 2022
Background: Pharmaceutical expenditure grow strongly in most health care systems. Especially high prices of new drugs are perceived to be driver of growth which might threaten the sustainability of financing drugs. Objective: The study aims to analyse a) whether German health policies can...
Persistent link: https://www.econbiz.de/10013271336
Cover Image
Pharmaceutical expenditure in Germany : future development, political influence and economic impact
Wolf, Sascha G. - 2009 - 1. Aufl. 2009
ökonometrischer Tests wird gezeigt, dass die Gesundheitspolitik in der Vergangenheit durch wahl- und klientelorientierte … ökonometrischer Tests wird gezeigt, dass die Gesundheitspolitik in der Vergangenheit durch wahl- und klientelorientierte …
Persistent link: https://www.econbiz.de/10011674632